Novo Nordisk reported DKK1.5B in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Bausch Health Companies USD 398M 2M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Pacira USD 112.4M 108.78M Sep/2026
Sanofi EUR 222M 65M Sep/2026
Supernus Pharmaceuticals USD 718K 1.6M Sep/2026